BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bui Han SH, Martin P. Liver transplantation for hepatitis B. Hepatol Res. 2004;29:193-201. [PMID: 15288010 DOI: 10.1016/j.hepres.2004.02.015] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 0.6] [Reference Citation Analysis]
Number Citing Articles
1 Rahimi R, Hosseini SY, Fattahi MR, Sepehrimanesh M, Safarpour A, Malekhosseini SA, Nejabat M, Khodadad M, Ardebili M. YMDD Motif Mutation Profile Among Patients Receiving Liver Transplant Due to Hepatitis B Virus Infection With Long Term Lamivudine/Immunoglobulin Therapy. Hepat Mon 2015;15:e27120. [PMID: 26300928 DOI: 10.5812/hepatmon.27120v2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.1] [Reference Citation Analysis]
2 Yuefeng M, Weili F, Wenxiang T, Ligang X, Guiling L, Hongwei G, Wencai L, Xiaoguang W, Wei M, Zhongyi F. Long-term outcome of patients with lamivudine after early cessation of hepatitis B immunoglobulin for prevention of recurrent hepatitis B following liver transplantation. Clin Transplant. 2011;25:517-522. [PMID: 20560989 DOI: 10.1111/j.1399-0012.2010.01290.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
3 Xu X, Tu Z, Wang B, Ling Q, Zhang L, Zhou L, Jiang G, Wu J, Zheng S. A novel model for evaluating the risk of hepatitis B recurrence after liver transplantation. Liver Int. 2011;31:1477-1484. [PMID: 21745275 DOI: 10.1111/j.1478-3231.2011.02500.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
4 Dong C, Gao W, Ma N, Sun C, Zheng WP, Wang K, Shen ZY. Risks and treatment strategies for de novo hepatitis B virus infection from anti-HBc-positive donors in pediatric living donor liver transplantation. Pediatr Transplant. 2017;21. [PMID: 27933716 DOI: 10.1111/petr.12854] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
5 Guo YM, Li FY, Gong M, Zhang L, Wang JB, Xiao XH, Li J, Zhao YL, Wang LF, Zhang XF. Short-term efficacy of treating hepatitis B virus-related acute-on-chronic liver failure based on cold pattern differentiation with hot herbs: A randomized controlled trial. Chin J Integr Med 2016;22:573-80. [PMID: 27220737 DOI: 10.1007/s11655-016-2582-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
6 Thung SN. Histologic findings in recurrent HBV. Liver Transpl 2006;12:S50-3. [DOI: 10.1002/lt.20946] [Cited by in Crossref: 30] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
7 Yuan C, Xiu D, Jiang B, Li Z, Li L, Song S, Zhang T. HBV recurrence lowered by lamivudine/HBIG combination therapy in liver transplant patients: ten-year experience. Hepatobiliary & Pancreatic Diseases International 2013;12:149-53. [DOI: 10.1016/s1499-3872(13)60024-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
8 Suehiro T, Shimada M, Kishikawa K, Shimura T, Soejima Y, Yoshizumi T, Hashimoto K, Mochida Y, Maehara Y, Kuwano H. Prevention of hepatitis B virus infection from hepatitis B core antibody-positive donor graft using hepatitis B immune globulin and lamivudine in living donor liver transplantation. Liver Int. 2005;25:1169-1174. [PMID: 16343068 DOI: 10.1111/j.1478-3231.2005.01165.x] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 1.7] [Reference Citation Analysis]
9 Kogure T, Ueno Y, Kawagishi N, Kanno N, Yamagiwa Y, Fukushima K, Satomi S, Shimosegawa T. The model for end-stage liver disease score is useful for predicting economic outcomes in adult cases of living donor liver transplantation. J Gastroenterol 2006;41:1005-10. [PMID: 17096070 DOI: 10.1007/s00535-006-1887-x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 1.1] [Reference Citation Analysis]
10 Buti M, Mas A, Prieto M, Casafont F, González A, Miras M, Herrero JI, Jardi R, Esteban R. Adherence to Lamivudine after an early withdrawal of hepatitis B immune globulin plays an important role in the long-term prevention of hepatitis B virus recurrence. Transplantation. 2007;84:650-654. [PMID: 17876280 DOI: 10.1097/01.tp.0000277289.23677.0a] [Cited by in Crossref: 83] [Cited by in F6Publishing: 65] [Article Influence: 5.5] [Reference Citation Analysis]
11 Rao W, Wu X, Xiu D. Lamivudine or lamivudine combined with hepatitis B immunoglobulin in prophylaxis of hepatitis B recurrence after liver transplantation: a meta-analysis. Transpl Int. 2009;22:387-394. [PMID: 19017304 DOI: 10.1111/j.1432-2277.2008.00784.x] [Cited by in Crossref: 48] [Cited by in F6Publishing: 37] [Article Influence: 3.4] [Reference Citation Analysis]
12 Huang K, Hu JH, Wang HF, He WP, Chen J, Duan XZ, Zhang AM, Liu XY. Survival and prognostic factors in hepatitis B virus-related acute-on-chronic liver failure. World J Gastroenterol 2011; 17(29): 3448-3452 [PMID: 21876637 DOI: 10.3748/wjg.v17.i29.3448] [Cited by in CrossRef: 37] [Cited by in F6Publishing: 35] [Article Influence: 3.4] [Reference Citation Analysis]